At May 31, 2008 Replidyne had cash and short term investments totaling $71.5 million.
About Replidyne, Inc.
Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne's lead program is an investigational antibacterial agent REP3123 that targets Gram-positive Clostridium difficile (C. difficile) bacteria and C. difficile Infection (CDI). Replidyne is pursuing the development of other novel anti-infective programs based on its DNA replication inhibition technology and its in-house discovery research.
This press release contains plans, intentions, objectives, estimates
and expectations that constitute forward-looking statements about
Replidyne, Inc. that involve significant risks and uncertainties. Actual
results could differ materially from those discussed due to a number of
factors including, the success and timing of pre-clinical studies and
clinical trials; the Company's ability to obtain and maintain regulatory
approval of product candidates and the labeling under any approval that may
be obtained; plans to develop and commercialize product candidates; the
loss of key scientific or management personnel; the size and growth of the
potential markets for the Company's product candidates and the Company's
ability to serve those markets; regulatory developments in the U.S. and
foreign countries; the rate and degree of market acceptance of any future
products; the accuracy of Company estimates regarding expenses, future
revenues and capital requirements; the Company's ability to obtain and
maintain intellectual property protection for our product candidates; the
successful development of the Company's sales and marketing capabilities;
the success of competing drugs that are or become available; and the
performance of third party manufacturers. These and additional risks and
uncertainties are described more fully in the
|SOURCE Replidyne, Inc.|
Copyright©2008 PR Newswire.
All rights reserved